Xi Yang, Hannah L Nathan, Ebruba E Oyekan, Tim I M Korevaar, Doaa Ahmed, Katherine Pacifico, Aisha Hameed, Manju Chandiramani, Anita Banerjee, Caroline Ovadia
{"title":"开发一种风险分层工具来预测妊娠期糖尿病患者胰岛素治疗的风险:一项队列研究。","authors":"Xi Yang, Hannah L Nathan, Ebruba E Oyekan, Tim I M Korevaar, Doaa Ahmed, Katherine Pacifico, Aisha Hameed, Manju Chandiramani, Anita Banerjee, Caroline Ovadia","doi":"10.3390/jpm15060223","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> We aimed to develop and validate a simple, easy-to-use risk stratification tool to use in the diagnosis of gestational diabetes mellitus (GDM) to triage those more likely to require insulin treatment. <b>Methods</b>: Using an audit of patients with GDM in 2019, multivariable logistic regression was used to select variables and develop a prediction model for insulin requirement. A stratification tool was developed by dichotomising these selected variables; its performance was assessed with an internal cohort from 2021 and externally from patients managed at a separate hospital. <b>Results</b>: Patients with a higher fasting blood glucose concentration (OR 2.41, 95% CI 1.84-3.15) and higher booking body mass index (OR 1.48, 95% CI 1.07-2.03) were more likely to require insulin therapy whilst a later gestational-weeks-at-diagnosis value gave a lower risk of insulin therapy (OR 0.71, 95% CI 0.62-0.81 per week). The low-risk group for insulin requirement was defined thus: fasting blood glucose < 5.6 mmol/L, booking BMI < 30 kg/m<sup>2</sup>, and gestational weeks at diagnosis ≥ 24 weeks. This classification had a negative predictive value (NPV) of 94% for insulin requirement, with a sensitivity of 84% and specificity of 56% in the development cohort. Similarly, in the internal and external validation cohorts, the NPVs were 93 and 90%, with sensitivity values of 77 and 78%, respectively. <b>Conclusions</b>: This study developed a pragmatic tool with three criteria for stratifying the GDM group not requiring insulin treatment, with successful validation for clinical use.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194323/pdf/","citationCount":"0","resultStr":"{\"title\":\"Developing a Risk Stratification Tool to Predict Patients with Gestational Diabetes Mellitus at Risk of Insulin Treatment: A Cohort Study.\",\"authors\":\"Xi Yang, Hannah L Nathan, Ebruba E Oyekan, Tim I M Korevaar, Doaa Ahmed, Katherine Pacifico, Aisha Hameed, Manju Chandiramani, Anita Banerjee, Caroline Ovadia\",\"doi\":\"10.3390/jpm15060223\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives:</b> We aimed to develop and validate a simple, easy-to-use risk stratification tool to use in the diagnosis of gestational diabetes mellitus (GDM) to triage those more likely to require insulin treatment. <b>Methods</b>: Using an audit of patients with GDM in 2019, multivariable logistic regression was used to select variables and develop a prediction model for insulin requirement. A stratification tool was developed by dichotomising these selected variables; its performance was assessed with an internal cohort from 2021 and externally from patients managed at a separate hospital. <b>Results</b>: Patients with a higher fasting blood glucose concentration (OR 2.41, 95% CI 1.84-3.15) and higher booking body mass index (OR 1.48, 95% CI 1.07-2.03) were more likely to require insulin therapy whilst a later gestational-weeks-at-diagnosis value gave a lower risk of insulin therapy (OR 0.71, 95% CI 0.62-0.81 per week). The low-risk group for insulin requirement was defined thus: fasting blood glucose < 5.6 mmol/L, booking BMI < 30 kg/m<sup>2</sup>, and gestational weeks at diagnosis ≥ 24 weeks. This classification had a negative predictive value (NPV) of 94% for insulin requirement, with a sensitivity of 84% and specificity of 56% in the development cohort. Similarly, in the internal and external validation cohorts, the NPVs were 93 and 90%, with sensitivity values of 77 and 78%, respectively. <b>Conclusions</b>: This study developed a pragmatic tool with three criteria for stratifying the GDM group not requiring insulin treatment, with successful validation for clinical use.</p>\",\"PeriodicalId\":16722,\"journal\":{\"name\":\"Journal of Personalized Medicine\",\"volume\":\"15 6\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194323/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Personalized Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jpm15060223\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15060223","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
目的:我们旨在开发和验证一个简单,易于使用的风险分层工具,用于妊娠糖尿病(GDM)的诊断,以分类那些更可能需要胰岛素治疗的患者。方法:通过对2019年GDM患者的审计,采用多变量logistic回归选择变量,建立胰岛素需求预测模型。通过对这些选定的变量进行二分类,开发了分层工具;其绩效通过2021年的内部队列和在另一家医院管理的外部患者进行评估。结果:较高的空腹血糖浓度(OR 2.41, 95% CI 1.84-3.15)和较高的身体质量指数(OR 1.48, 95% CI 1.07-2.03)的患者更有可能需要胰岛素治疗,而较晚的妊娠周诊断值则降低胰岛素治疗的风险(OR 0.71, 95% CI 0.62-0.81 /周)。胰岛素需求低危组定义为:空腹血糖< 5.6 mmol/L,预定BMI < 30 kg/m2,诊断时妊娠周数≥24周。该分类对胰岛素需求的阴性预测值(NPV)为94%,在发展队列中敏感性为84%,特异性为56%。同样,在内部和外部验证队列中,npv分别为93和90%,敏感性值分别为77和78%。结论:本研究开发了一个实用的工具,有三个标准来划分不需要胰岛素治疗的GDM组,并成功验证了临床应用。
Developing a Risk Stratification Tool to Predict Patients with Gestational Diabetes Mellitus at Risk of Insulin Treatment: A Cohort Study.
Objectives: We aimed to develop and validate a simple, easy-to-use risk stratification tool to use in the diagnosis of gestational diabetes mellitus (GDM) to triage those more likely to require insulin treatment. Methods: Using an audit of patients with GDM in 2019, multivariable logistic regression was used to select variables and develop a prediction model for insulin requirement. A stratification tool was developed by dichotomising these selected variables; its performance was assessed with an internal cohort from 2021 and externally from patients managed at a separate hospital. Results: Patients with a higher fasting blood glucose concentration (OR 2.41, 95% CI 1.84-3.15) and higher booking body mass index (OR 1.48, 95% CI 1.07-2.03) were more likely to require insulin therapy whilst a later gestational-weeks-at-diagnosis value gave a lower risk of insulin therapy (OR 0.71, 95% CI 0.62-0.81 per week). The low-risk group for insulin requirement was defined thus: fasting blood glucose < 5.6 mmol/L, booking BMI < 30 kg/m2, and gestational weeks at diagnosis ≥ 24 weeks. This classification had a negative predictive value (NPV) of 94% for insulin requirement, with a sensitivity of 84% and specificity of 56% in the development cohort. Similarly, in the internal and external validation cohorts, the NPVs were 93 and 90%, with sensitivity values of 77 and 78%, respectively. Conclusions: This study developed a pragmatic tool with three criteria for stratifying the GDM group not requiring insulin treatment, with successful validation for clinical use.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.